Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID

S. E. Kasner, M. J. Lynn, M. I. Chimowitz, M. R. Frankel, H. Howlett-Smith, V. S. Hertzberg, S. Chaturvedi, S. R. Levine, B. J. Stern, C. G. Benesch, T. G. Jovin, C. A. Sila, J. G. Romano

Research output: Contribution to journalArticle

124 Scopus citations

Abstract

The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

Original languageEnglish (US)
Pages (from-to)1275-1278
Number of pages4
JournalNeurology
Volume67
Issue number7
DOIs
StatePublished - Oct 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Kasner, S. E., Lynn, M. J., Chimowitz, M. I., Frankel, M. R., Howlett-Smith, H., Hertzberg, V. S., Chaturvedi, S., Levine, S. R., Stern, B. J., Benesch, C. G., Jovin, T. G., Sila, C. A., & Romano, J. G. (2006). Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID. Neurology, 67(7), 1275-1278. https://doi.org/10.1212/01.wnl.0000238506.76873.2f